Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cancer pharmacogenetics.

S Marsh1, H L McLeod

  • 1Department of Medicine, Washington University School of Medicine, 660 South Euclid Ave, Campus Box 8069, the Siteman Cancer Center, and the CREATE Pharmacogenetic Research Network, St Louis, MO 63110-1093, USA.

British Journal of Cancer
|January 8, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Update on the management of patients with HIV infection in anaesthesia and critical care.

BJA education·2023
Same author

Perioperative considerations for transgender and gender diverse adults.

BJA education·2023
Same author

<i>In vitro</i> Exposure to Inflammatory Mediators Affects the Differentiation of Mesenchymal Progenitors.

Frontiers in bioengineering and biotechnology·2022
Same author

Dermatological complications of critical care.

BJA education·2021
Same author

Life-threatening skin conditions presenting to critical care.

BJA education·2021
Same author

Steroid use in critical care.

BJA education·2021
Same journal

De novo cancer-related mortality after solid organ transplantation in England: the EpCOT study.

British journal of cancer·2026
Same journal

Planetary Health Diet Index and breast cancer risk.

British journal of cancer·2026
Same journal

Can national lung cancer screening programs be implemented without exacerbating social disparities?

British journal of cancer·2026
Same journal

Differences in overall survival for invasive epithelial ovarian cancer by race and ethnicity: results from the Ovarian Cancer Association Consortium.

British journal of cancer·2026
Same journal

Circulating metabolite biomarkers associated with prostate cancer risk in Black Americans: findings from the Southern Community Cohort Study.

British journal of cancer·2026
Same journal

Ovarian cancer tumor immune profiles associated with intrauterine device and oral contraceptive use.

British journal of cancer·2026
See all related articles

Pharmacogenetics and pharmacogenomics help personalize cancer treatment by studying how genetic variations affect chemotherapy response and toxicity. This guides better, individualized patient care for improved outcomes.

Area of Science:

  • Oncology
  • Pharmacogenetics
  • Genomics

Background:

  • Numerous combination chemotherapy regimens exist for various cancers.
  • Individual patient responses to chemotherapy vary significantly.
  • Personalized medicine requires understanding the genetic basis of drug response.

Purpose of the Study:

  • To review studies on genetic polymorphisms in drug-metabolizing enzymes and targets.
  • To assess the impact of these polymorphisms on chemotherapy toxicity and efficacy.
  • To highlight the role of pharmacogenomics in identifying patients at risk for adverse drug reactions.

Main Methods:

  • Literature review of pharmacogenetic and pharmacogenomic studies.
  • Analysis of polymorphisms in key drug-metabolizing enzymes.

Related Experiment Videos

  • Assessment of polymorphisms in chemotherapy drug targets.
  • Evaluation of impact on drug toxicity and patient response.

    • Main Results:

    • Genetic variations influence patient response to chemotherapy.
    • Polymorphisms in enzymes and targets affect drug efficacy and toxicity.
    • Pharmacogenetic data can predict adverse drug reactions.
    • Polygenic approaches are needed for comprehensive risk assessment.

    Conclusions:

    • Pharmacogenetics and pharmacogenomics are crucial for individualizing cancer therapy.
    • Understanding genetic variations improves chemotherapy selection and dosing.
    • Polygenic pharmacogenomic strategies are essential for minimizing adverse events and optimizing treatment outcomes.